<DOC>
	<DOCNO>NCT02897648</DOCNO>
	<brief_summary>The route subcutaneous administration drug become common practice specialty ( palliative care , geriatrics ) . This alternative oral , sublingual , rectal intravenous Many drug use subcutaneous route clinical study evaluate level scientific relevance justifies use . The purpose study ass : 1 . / Determine difference subcutaneously compare intravenous administration term dosage serum PK / PD Beta lactam objective geriatric population . 2 . / The safety lack toxicity administration subcutaneously . Advantages disadvantage - easy Of establishment - Simplicity Monitoring manipulation - Reduced Risk infection - No Risk venous thrombosis - Lower cost Simple -Technique support home take - Limitation Aggressive gesture - multiplicity Of possible injection sit - Technique Of choice agitate patient confused -Risk localize edema ( &lt; 1000mL / 24 / site ) - Use Impossible drug - Risk Discomfort intolerance injection site A practical study conduct among 382 physician ( 289 geriatrician 93 infectious disease specialist ) . Among 97.5 % report regular use subcutaneous route administration antibiotic . Declarative criterion pretend curb use route lack data Pk / Pd ( 61.2 % ) ; absence marketing authorization subcutaneous route ( 34.5 % ) ; absence serum assay available ( 2.1 % ) .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic / Pharmacodynamic Tolerance Assessment Dermal Administration Beta-lactams Elderly</brief_title>
	<detailed_description>PROTOCOL Primary objective : • Determine difference subcutaneously compare intravenous administration term dosage serum PK / PD objectives Beta lactam geriatric population . Secondary objective : - Clinical evaluation J14 J90 ( heal , death ) - Clinical tolerance subcutaneously self-assessment hetero-evaluation existence cognitive disorder Monitoring antibiotic dosage : - Making systematic assay serum concentration residual antibiotic range 30 min prior reinjection H24 start treatment weekly monitoring . - Realization assay accord method Liquid Chromatography-Mass Spectrometry ( LC-MS ) Patient monitor J1-J14 : • Clinical monitoring biological usual</detailed_description>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Geriatric Population ( ≥ 75 year ) Infection may cause bacteremia : Gramnegative bacillus grampositive cocci susceptible betalactam Patient Refusal express legal guardian polymicrobial infection</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>